CIK 0001472091 · Non-accelerated filer<br>Smaller reporting company
PDS Biotechnology Corp
Sign in to watch- Ticker
- PDSB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264231384
- Phone
- 800-208-3343
- Business address
- 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- Edge Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-11 | BRAWLEY OTIS W Director | Grant or award · Employee Stock Option (Right to Buy) | +22,700 | 22,700 | ||
| 2025-06-11 | Iliev Ilian Director | Grant or award · Employee Stock Option (Right to Buy) | +22,700 | 22,700 | ||
| 2025-06-11 | Ali-Jackson Kamil Director | Grant or award · Employee Stock Option (Right to Buy) | +22,700 | 22,700 | ||
| 2025-06-11 | Freitag Gregory Gene Director | Grant or award · Employee Stock Option (Right to Buy) | +22,700 | 22,700 | ||
| 2025-06-11 | Glover Stephen C. Director | Grant or award · Employee Stock Option (Right to Buy) | +22,700 | 22,700 | ||
| 2025-02-28 | Freitag Gregory Gene Director | Purchase | +15,060 | $1.66 | $25K | 61,213 |
| 2025-02-28 | Freitag Gregory Gene Director | Purchase · Common Warrant | +15,060 | 15,060 | ||
| 2025-02-28 | Glover Stephen C. Director | Purchase | +15,061 | $1.66 | $25K | 78,851 |
| 2025-02-28 | Glover Stephen C. Director | Purchase · Common Warrant | +15,061 | 15,061 | ||
| 2024-06-24 | Freitag Gregory Gene Director | Grant or award · Employee Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2024-06-24 | Glover Stephen C. Director | Grant or award · Employee Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2024-06-24 | SYKES RICHARD Director | Grant or award · Employee Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2024-06-24 | Iliev Ilian Director | Grant or award · Employee Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2024-06-24 | BRAWLEY OTIS W Director | Grant or award · Employee Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2024-06-24 | Ali-Jackson Kamil Director | Grant or award · Employee Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2024-05-01 | Toutain Stephan Chief Operations Officer | Grant or award · Employee Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-02-28 | BEDU-ADDO FRANK President/CEO | Grant or award · Employee Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-02-28 | Brown Spencer D. Senior VP, General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +56,000 | 56,000 | ||
| 2024-02-28 | CONN GREGORY Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +46,648 | 46,648 | ||
| 2024-01-22 | Shepard Kirk V. Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +200,000 | 200,000 |
Page 2 of 6 · 118 trades